HUNTSVILLE, Ala.–(BUSINESS WIRE)–Kailos Genetics, a personalized medicine information company offering leading-edge gene-based testing, announced they have entered into a collaboration with Huntsman Cancer Institute (HCI) at the University of Utah to develop a clinical-grade test for circulating tumor DNA (ctDNA). Backed by a $2.4 million grant from the National Institutes of Health (NIH), the minimally invasive test will be used to monitor patients for breast cancer disease recurrence.
“When academic and commercial organizations collaborate, we are able to see exciting advances in research be practically applied within the consumer and clinical space,” said Troy Moore, chief scientific officer at Kailos Genetics.
Read the full press release here.
